Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NKTR118 Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NKTR118 Formulation 1 | EXPERIMENTAL | Fasted |
| NKTR118 Formulation 2 | EXPERIMENTAL | Fasted |
| NKTR118 Formulation 3 | EXPERIMENTAL | Fasted |
| NKTR118 Formulation 1a | EXPERIMENTAL | Fed |
| NKTR118 Formulation 3a | EXPERIMENTAL | FED |
| Name | Type | Description |
|---|---|---|
| NKTR118 Formulation 1 | DRUG | Oral dose, 25 mg |
| NKTR118 Formulation 2 | DRUG | Oral dose, 25 mg |
| NKTR118 Formulation 3 | DRUG | Oral dose, 25 mg |
| NKTR118 Formulation 1a | DRUG | Oral dose, 25 mg |
| NKTR118 Formulation 3a | DRUG | Oral dose, 25 mg |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study-specific procedures * Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating, and must be of non-childbearing potential, confirmed at screening by f...
NKTR118 Formulation 1 is an investigational small molecule being studied in healthy volunteers. It is being evaluated in a Phase 1 clinical trial to assess the relative bioavailability of NKTR-118 in three formulations. The drug is not approved and is still in clinical development.
NKTR118 Formulation 1 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials to evaluate this investigational small molecule drug.
NKTR118 Formulation 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
NKTR118 Formulation 1 has one completed clinical trial, NCT01365000, titled 'Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.' This Phase 1 study enrolled 21 participants in the United States and was a controlled, randomized trial.
NKTR118 Formulation 1 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT01365000, was a bioavailability study in healthy volunteers, and the drug has not yet progressed to later-stage trials or approval.